Logo

financial estimates

In Brief This Week: Beckman Coulter, Quest Diagnostics, Guardant Health, Diasorin, More

News items for the week of Jan. 27, 2025.

In Brief This Week: Revvity, IntelliGenome, Angle, NowDiagnostics, Pramana

News items for the week of Jan. 20, 2025.

Top Five Articles on 360Dx Last Week: Interest in JP Morgan Healthcare Conference Runs High; More

Last week, readers were most interested in company updates presented at the JP Morgan Healthcare Conference.

In Brief This Week: Accelerate Diagnostics, MDxHealth, Mayo Clinic; Sysmex America, More

News items for the week of Jan. 13, 2025.

At JP Morgan, Myriad Genetics Says Q4 Test Volumes Disappointing, Firm Preps New Launches in 2025
Premium

The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.

Jan 15, 2025

Natera Provides New Product, Clinical Evidence Updates at JPM
Premium

Jan 14, 2025

Danaher CEO Outlines Financials and China Expectations at JP Morgan
Premium

Jan 14, 2025

Quanterix Preliminary Q4 2024 Revenues Jump 11 Percent

Jan 13, 2025

Exagen Posts Flat to Slight Decline in Preliminary Q4 Report, Gets Conditional NY Approval

Jan 10, 2025

Biodesix Preliminary Revenues up 39 Percent for Q4, 45 Percent for 2024

Nov 12, 2024

Quanterix Counting on Multi-Marker Approach as Differentiator in Crowded Alzheimer's Dx Field
Premium

Oct 9, 2024

Myriad Genetics Enters Collaborations to Study MRD, Announces Preliminary Q3 Revenue Estimates

Sep 6, 2024

In Brief This Week: Danaher; Seegene; Mainz Biomed

Jul 8, 2024

MDxHealth Preliminary Q2 Revenues up 32 Percent

May 9, 2024

QuidelOrtho Suspends Guidance After Lowering Full-Year Expectations on COVID, Savanna MDx Platform
Premium

May 3, 2024

Fulgent Genetics Core Q1 Revenues Grow 1 Percent

Feb 15, 2024

T2 Biosystems Preliminary Q4 Revenues Down 69 Percent

Jan 8, 2024

Veracyte Acquires C2i Genomics for up to $95M, Reports Prelim Q4, Full-Year Revenue Growth

Nov 20, 2023

Agilent Diagnostics and Genomics Group Revenues up Slightly in Q4 as Overall Sales Decline 9 Percent

Oct 27, 2023

Bio-Rad Again Lowers Guidance After Q3 Revenue Miss, Sharp Sales Decline in Life Science Segment
Premium

Oct 12, 2023

QuidelOrtho Expects Q3 Revenues Well Above Wall Street Estimate

May 9, 2023

Quanterix Q1 Revenues Fall 4 Percent as Instrument Sales Decline

Apr 3, 2023

Oncocyte Prices $13.9M Stock Offering, Reports 69 Percent Drop in Preliminary Q4 Revenues

Jan 9, 2023

Castle Biosciences Estimates 2022 Revenues in Line With Prior Projections

Jan 9, 2023

Exact Sciences Projects 28 Percent Bump in Total Q4 Oncology Revenue